Alexandria Real Estate Equities is thoroughly outperforming the Dow Jones U.S. Real Estate Index because of the high percentage of investment-grade biotech and pharma tenants it houses its buildings, says the company's CEO Joel Marcus. He says the fact that Alexandria's buildings are located in hot urban centers like New York, San Francisco and Cambridge is also a factor. Marcus says the cost of designing and maintaining buildings dedicated to science may be higher, but so are the rents.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

A High-Income Hedge Against the Coming Wave of Dividend Cuts

REITs, Real Estate and Donald Trump in 2017

3 Top REIT Plays Heading Into the Trump Presidency

This REIT Will Hold Up If the Market Soon Parties Like It's 1929

4 Big Short-Squeeze Stocks That Could Pop This December